Atara Biotherapeutics Stock Probability of Future Stock Price Finishing Over 19.52
| ATRA Stock | USD 11.47 0.86 8.11% |
Atara |
Atara Biotherapeutics Target Price Odds to finish over 19.52
The tendency of Atara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 19.52 or more in 90 days |
| 11.47 | 90 days | 19.52 | near 1 |
Based on a normal probability distribution, the odds of Atara Biotherapeutics to move over $ 19.52 or more in 90 days from now is near 1 (This Atara Biotherapeutics probability density function shows the probability of Atara Stock to fall within a particular range of prices over 90 days) . Probability of Atara Biotherapeutics price to stay between its current price of $ 11.47 and $ 19.52 at the end of the 90-day period is about 5.92 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.54 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Atara Biotherapeutics will likely underperform. Additionally Atara Biotherapeutics has an alpha of 0.8117, implying that it can generate a 0.81 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Atara Biotherapeutics Price Density |
| Price |
Predictive Modules for Atara Biotherapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Atara Biotherapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Atara Biotherapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Atara Biotherapeutics is not an exception. The market had few large corrections towards the Atara Biotherapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Atara Biotherapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Atara Biotherapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.81 | |
β | Beta against Dow Jones | 1.54 | |
σ | Overall volatility | 1.62 | |
Ir | Information ratio | 0.11 |
Atara Biotherapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Atara Biotherapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Atara Biotherapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Atara Biotherapeutics is way too risky over 90 days horizon | |
| Atara Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Atara Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.57 M. Net Loss for the year was (276.13 M) with profit before overhead, payroll, taxes, and interest of 63.57 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility |
Atara Biotherapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Atara Stock often depends not only on the future outlook of the current and potential Atara Biotherapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Atara Biotherapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 4.2 M | |
| Cash And Short Term Investments | 51.7 M |
Atara Biotherapeutics Technical Analysis
Atara Biotherapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Atara Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Atara Biotherapeutics. In general, you should focus on analyzing Atara Stock price patterns and their correlations with different microeconomic environments and drivers.
Atara Biotherapeutics Predictive Forecast Models
Atara Biotherapeutics' time-series forecasting models is one of many Atara Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Atara Biotherapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Atara Biotherapeutics
Checking the ongoing alerts about Atara Biotherapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Atara Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Atara Biotherapeutics is way too risky over 90 days horizon | |
| Atara Biotherapeutics appears to be risky and price may revert if volatility continues | |
| Atara Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 8.57 M. Net Loss for the year was (276.13 M) with profit before overhead, payroll, taxes, and interest of 63.57 M. | |
| Atara Biotherapeutics currently holds about 331.31 M in cash with (192.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.51. | |
| Atara Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: FUJIFILM Diosynth Biotechnologies Celebrates the Expansion Completion at its California Cell Therapy Facility |
Check out Atara Biotherapeutics Backtesting, Atara Biotherapeutics Valuation, Atara Biotherapeutics Correlation, Atara Biotherapeutics Hype Analysis, Atara Biotherapeutics Volatility, Atara Biotherapeutics History as well as Atara Biotherapeutics Performance. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.32) | Revenue Per Share 12.263 | Quarterly Revenue Growth 28.927 | Return On Assets (0.57) | Return On Equity (20.15) |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.